GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaRoth Labs Inc (GREY:ROTH) » Definitions » Change In Working Capital

PharmaRoth Labs (PharmaRoth Labs) Change In Working Capital : $-0.03 Mil (TTM As of Mar. 2011)


View and export this data going back to 2008. Start your Free Trial

What is PharmaRoth Labs Change In Working Capital?

PharmaRoth Labs's change in working capital for the quarter that ended in Mar. 2011 was $-0.01 Mil.

PharmaRoth Labs's change in working capital for the fiscal year that ended in Jun. 2010 was $-0.00 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).


PharmaRoth Labs Change In Working Capital Historical Data

The historical data trend for PharmaRoth Labs's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaRoth Labs Change In Working Capital Chart

PharmaRoth Labs Annual Data
Trend Jun08 Jun09 Jun10
Change In Working Capital
- 0.01 -

PharmaRoth Labs Quarterly Data
Mar07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.02 -0.02 0.02 -0.01

PharmaRoth Labs Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaRoth Labs Change In Working Capital Related Terms

Thank you for viewing the detailed overview of PharmaRoth Labs's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaRoth Labs (PharmaRoth Labs) Business Description

Traded in Other Exchanges
N/A
Address
8250 West Charleston Boulevard, Suite 110, Las Vegas, NV, USA, 89117
PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

PharmaRoth Labs (PharmaRoth Labs) Headlines